Clinical trial NCT02689167: Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma
Official title: Open Label, Randomised Multi-centre Phase II Study to Assess the Efficacy and Tolerability of Sunitinib by Dose Administration Regimen (Dose Modification or Dose Interruptions) in Patients With Advanced or Metastatic Renal Cell Carcinoma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Kidney Neoplasms
Metastatic Renal Cell Cancer
Keywords: renal cell carcinoma
sunitinib
metastatic
schedule
toxicity
safety
Lead sponsor: Centre Hospitalier Universitaire de Besancon
Sponsor class: OTHER
Collaborators: name: Pfizer
First posted: 2016-02-23
Enrollment: 226
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients who are candidates for first line treatment with Sunitinib 50mg 4/6 regimen in accordance with the Marketing Authorisation who meet the inclusion/exclusion criteria will be offered participation in this study during the consultation as part of their usual care. The patients will be included before Sunitinib treatment is started. Thereafter, sunitinib is initiated 50 mg/day; regimen 4/6 (Marketing Authorisation Indication), 4 weeks "on " alternating with 2 weeks "off "

As soon as a dose or schedule adjustment is required, regardless of cause, the patient will be randomised 1/1:

* Either into arm A and will receive 37.5mg of Sunitinib per day by the 4/6 regimen (in accordance with the Marketing Authorisation); 4 weeks "on " alternating with 2 weeks "off "
* Or into arm B and will receive 50mg of Sunitinib per day by the 2/3 regimen (investigational arm); 2 weeks "on " alternating with 1 week "off "


Eligibility criteria: Key Inclusion Criteria:

* Men or women over 18 years old
* Patients with local, advanced or inoperable or metastatic (MRCC) renal cell carcinoma who are starting first line treatment with Sunitinib 50mg (4/6 regimen) according to the Marketing Authorisation Indication
* Patients with histologically or cytologically confirmed renal cancer, clear cell variant or with a clear cell component
* Karnofsky performance status ≥ 70%
* Adequate organ function:

  * Absolute neutrophil (N) count ≥ 1 500 / µL
  * Platelets ≥ 100 000 / µL
  * Haemoglobin ≥ 10 g/dL
  * Adjusted serum calcium ≤ 2.6 mmol/L
  * Creatinine clearance ≥ 30 mL/min (by the MDRD formula)
  * Total bilirubin ≤ 1.5 x ULN (upper limit of the normal range)
  * AST ≤ 2.5 x ULN and ALT ≤ 2.5 x ULN OR AST and ALT ≤ 5 x ULN if liver abnormalities due to liver metastases AST = aspartate aminotransferase ALT = alanine aminotransferase

Key Exclusion Criteria:

* Renal carcinoma with no clear cell component.
* Previous systemic treatment for the RCC regardless of type (including targeted therapy, immunotherapy, chemotherapy, hormone or experimental therapy). Previous or concomitant treatment with a bisphosphonate or denosumab is allowed.
* Patients whose clinical state and comorbidities are not consistent with administration of Sunitinib at the initial dose of 50mg/day 4 weeks out of 6.
* Grade 3 haemorrhage within 4 weeks before starting treatment with Sunitinib (according to the NCI-CTCAE toxicity score version 3.0).
* The presence of a past history of cancer in the 3 years before inclusion into the study
* Major surgery within 4 weeks before sunitinib initiation
* Past history of symptomatic cerebral metastases, spinal cord compression or meningeal carcinomatosis. Patients with cerebral metastases discovered incidentally on imaging and who are asymptomatic are not excluded if these metastases have been treated (radiotherapy and/or surgery) with a period of at least 4 weeks between the end of treatment and inclusion into the study and no clinical or radiological signs of relapse, and corticosteroid dose is not exceeding 10mg/day of prednisone or equivalent. Subjects will be excluded if subjects have signs of grade ≥ 2 treatment-related complications.
* Any of the following features within 6 months of the administration of Sunitinib: myocardial infarction, severe/unstable angina, coronary artery/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack.
* Pulmonary embolism or deep vein thrombosis within 3 months of inclusion (unless it's stable, asymptomatic and treated with a low molecular weight heparin for at least 6 weeks before inclusion).
* Any known acute or chronic disorder (such as severe chronic obstructive pulmonary disease) which in the opinion of the investigator could impact on the patient's capacity to receive the study treatment or make interpretation of toxicity or adverse events difficult.
* Known HIV infection.
* History of chronic active hepatitis including subjects who are carriers of the hepatitis B (HBV) or hepatitis C (HCV) virus.
* Existence of uncontrolled infection.
* Uncontrolled hypertension defined as a blood pressure of \> 150 mmHg systolic or \> 100 mmHg diastolic despite optimal anti-hypertensive therapy (blood pressure must be controlled at inclusion).

Primary outcomes:
measure: MDT (median duration of treatment)
timeFrame: 12 mo
Secondary outcomes:
measure: PFS (progression-free survival)
timeFrame: 12 months
measure: OS (overall survival)
timeFrame: 30 months
measure: duration of sunitinib post randomization
timeFrame: 12 months
measure: time to randomization
timeFrame: 4 months
measure: ORR (objective response rate)
timeFrame: 6 months
measure: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
timeFrame: 24 months
measure: QOL (quality of life)
timeFrame: 24 months
Other outcomes:
Locations:
city: Besancon
country: France
facility: CHU Besancon
state: Franche-Comté
Study officials:
affiliation: Centre Hospitalier Universitaire de Besancon
name: antoine thiery-vuillemin, MD PhD
role: PRINCIPAL_INVESTIGATOR
References: